KR100913984B1 - 플라비바이러스 감염 예방용 핵산 백신 - Google Patents

플라비바이러스 감염 예방용 핵산 백신 Download PDF

Info

Publication number
KR100913984B1
KR100913984B1 KR1020037013021A KR20037013021A KR100913984B1 KR 100913984 B1 KR100913984 B1 KR 100913984B1 KR 1020037013021 A KR1020037013021 A KR 1020037013021A KR 20037013021 A KR20037013021 A KR 20037013021A KR 100913984 B1 KR100913984 B1 KR 100913984B1
Authority
KR
South Korea
Prior art keywords
antigen
virus
protein
gly
flavivirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020037013021A
Other languages
English (en)
Korean (ko)
Other versions
KR20030092051A (ko
Inventor
궝-젠 제이. 창
Original Assignee
더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 애즈 레프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비시즈, 센터스 포 디지즈 컨트롤 앤드 프리벤션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 애즈 레프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비시즈, 센터스 포 디지즈 컨트롤 앤드 프리벤션 filed Critical 더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 애즈 레프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비시즈, 센터스 포 디지즈 컨트롤 앤드 프리벤션
Publication of KR20030092051A publication Critical patent/KR20030092051A/ko
Application granted granted Critical
Publication of KR100913984B1 publication Critical patent/KR100913984B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
KR1020037013021A 2001-04-04 2002-04-04 플라비바이러스 감염 예방용 핵산 백신 Expired - Lifetime KR100913984B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/826,115 2001-04-04
US09/826,115 US7227011B2 (en) 1998-06-04 2001-04-04 Nucleic acid vaccines for prevention of flavivirus infection
PCT/US2002/010764 WO2002081754A1 (en) 2001-04-04 2002-04-04 Nucleic acid vaccines for prevention of flavivirus infection

Publications (2)

Publication Number Publication Date
KR20030092051A KR20030092051A (ko) 2003-12-03
KR100913984B1 true KR100913984B1 (ko) 2009-08-25

Family

ID=25245753

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020037013021A Expired - Lifetime KR100913984B1 (ko) 2001-04-04 2002-04-04 플라비바이러스 감염 예방용 핵산 백신

Country Status (11)

Country Link
US (6) US7227011B2 (enExample)
EP (3) EP1383931A4 (enExample)
JP (2) JP4448281B2 (enExample)
KR (1) KR100913984B1 (enExample)
CN (2) CN101002936A (enExample)
BR (1) BRPI0208301B8 (enExample)
CA (1) CA2443323C (enExample)
MX (1) MXPA03008838A (enExample)
NZ (1) NZ529106A (enExample)
WO (1) WO2002081754A1 (enExample)
ZA (1) ZA200307580B (enExample)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7227011B2 (en) * 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
DE60131430T2 (de) 2000-01-14 2008-10-16 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Oligodeoxynukleotide und ihre verwendung zur induktion einer immunreaktion
US20040037848A1 (en) * 2001-04-06 2004-02-26 Audonnet Jean-Christophe Francis Recombinant vaccine against West Nile Virus
US7740863B2 (en) * 2001-04-06 2010-06-22 Merial Recombinant vaccine against West Nile Virus
US20050031641A1 (en) * 2001-04-06 2005-02-10 Loosmore Sheena May Recombinant vaccine against West Nile Virus
FR2823222B1 (fr) * 2001-04-06 2004-02-06 Merial Sas Vaccin contre le virus de la fievre du nil
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
JP4718778B2 (ja) * 2001-07-27 2011-07-06 ワイス・エルエルシー ウエストナイルワクチン
WO2003020884A2 (en) * 2001-08-14 2003-03-13 The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services Method for rapid generation of mature dendritic cells
US8466116B2 (en) 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
AU2002366710A1 (en) 2001-12-20 2003-07-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
WO2004040263A2 (en) * 2002-10-31 2004-05-13 Health Research, Inc. Diagnostic test for west nile virus
WO2004016586A2 (en) * 2002-08-16 2004-02-26 Board Of Regents The University Of Texas System Compositions and methods related to flavivirus envelope protein domain iii antigens
US8263091B2 (en) * 2002-09-18 2012-09-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
WO2004044220A2 (en) * 2002-11-08 2004-05-27 The Administrators Of The Tulane Educational Fund Flaviviris fusion inhibitors
CA2432738A1 (en) * 2003-02-26 2004-08-26 Philippe Despres New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications
US8475808B2 (en) 2003-05-23 2013-07-02 Novartis Vaccines And Diagnostics, Inc. Immunogenic reagents from west nile virus
US7060280B2 (en) * 2003-06-11 2006-06-13 Academia Sinica Immunization against flavivirus
EP1664786B1 (en) 2003-09-09 2014-11-12 Idexx Laboratories, Inc. Detection of west nile virus infection and vaccination
US7074555B2 (en) 2004-04-28 2006-07-11 Idexx Laboratories, Inc. Detection of West Nile Virus
US20080118528A1 (en) * 2004-05-04 2008-05-22 Tsanyang Jake Liang Synthesis and Purification of West Nile Virus Virus-Like Particles
CN103088038B (zh) * 2004-07-12 2015-06-24 美国天甲生物医药有限公司 黄病毒疫苗
US7906292B2 (en) 2004-07-27 2011-03-15 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes and methods for their use
US7482017B2 (en) * 2004-09-09 2009-01-27 Research Development Foundation Flavivirus variants having phenotypic variation and immunogenic compositions thereof
JP4993301B2 (ja) * 2004-10-20 2012-08-08 サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー 日本脳炎ウイルスおよび西ナイルウイルスに対するワクチン
AU2006232865A1 (en) * 2005-04-01 2006-10-12 Wyeth Use of WNV DNA vaccine in combination with a conventional vaccine to overcome immunogen interference
EP2425856A1 (en) 2005-04-08 2012-03-07 Wyeth LLC Multivalent pneumococcal polysaccharide-protein conjugate composition
MX2007016083A (es) 2005-06-24 2008-03-10 Intervet Int Bv Vacunas quimericas inactivadas y metodos relacionados de uso.
US7455842B2 (en) * 2005-12-05 2008-11-25 University Of Kansas Chimeric West Nile viruses and uses thereof
US20070190617A1 (en) * 2006-02-13 2007-08-16 Chang-Jer Wu DNA vaccine for Japanese encephalitis virus
US20080044808A1 (en) * 2006-08-15 2008-02-21 Qian-Li Song West nile virus antigen and assay
ES2517615T3 (es) * 2006-11-09 2014-11-03 The United States Of America As Represented By The Secretary Of The Navy Inducción de una respuesta inmunitaria frente al virus del dengue usando un enfoque de sensibilización-refuerzo
EP2125024B1 (en) 2007-03-23 2013-02-13 TO-BBB Holding B.V. Targeted intracellular delivery of antiviral agents
JP2008263964A (ja) * 2007-03-29 2008-11-06 Yamaguchi Univ コウモリ由来細胞株
EP2003144A1 (en) * 2007-06-15 2008-12-17 Institut Pasteur Method for the diagnosis or the screening of an arbovirus infection, reagents useful in said method and their applications
WO2009024534A2 (en) * 2007-08-17 2009-02-26 Intercell Ag Japanese encephalitis virus (jev) and tick-borne encephalitis virus (tbev) peptides stimulating human t cell responses
US8138318B2 (en) * 2007-09-13 2012-03-20 Abbott Laboratories Hepatitis B pre-S2 nucleic acid
ES2685435T3 (es) * 2008-01-11 2018-10-09 Inovio Pharmaceuticals, Inc. Nuevas vacunas frente a múltiples subtipos del virus del dengue
WO2009098277A1 (en) * 2008-02-08 2009-08-13 Intercell Ag Flaviviridae mutants comprising a deletion in the capsid protein for use as vaccines
WO2009130261A1 (en) * 2008-04-22 2009-10-29 Cytos Biotechnology Ag Vaccine compositions for the treatment of dengue fever and uses thereof
CN101333246B (zh) * 2008-07-30 2011-04-13 中国农业科学院哈尔滨兽医研究所 乙型脑炎病毒e蛋白中和性b细胞抗原表位多肽及其应用
MX2011002071A (es) * 2008-08-29 2011-04-05 Boehringer Ingelheim Vetmed Vacuna para el virus del nilo occidental.
CN101607983B (zh) * 2009-07-29 2012-06-13 中国农业科学院哈尔滨兽医研究所 乙型脑炎病毒PrM/M蛋白B细胞抗原表位多肽及应用
DK2459709T3 (en) 2009-07-31 2014-12-01 Ge Healthcare Bio Sciences HIGH-REPLACED YELLOW FEBER VIRUS TREASURY WITH INCREASED CELL STORAGE
US20110182976A1 (en) * 2010-01-28 2011-07-28 National Taiwan Ocean University Lipoplex-patch based dna vaccine
MX2012012681A (es) * 2010-05-21 2012-12-17 Univ Pittsburgh Secuencias del virus de dengue universales y metodos de uso.
AR079970A1 (es) * 2010-07-23 2012-02-29 Xcellerex Inc Cepas de alto rendimiento del virus de la fiebre amarilla con una propagacion incrementada en las celulas
US20120294889A1 (en) * 2010-11-12 2012-11-22 Paxvax, Inc. Chimeric Flavivirus Vaccines
WO2012125525A2 (en) 2011-03-14 2012-09-20 Boehringer Ingelheim Vetmedica, Inc. Equine rhinitis vaccine
EP2768847A4 (en) 2011-10-20 2015-11-11 Us Gov Health & Human Serv DENGUE VIRUS E-GLYCOPROTEIN POLYPEPTIDES WITH MUTATIONS FOR ELIMINATING IMMUNOMINANT CROSS-REACTIVE EPITOPES
US8920804B2 (en) 2011-12-22 2014-12-30 Inbios International, Inc. Methods and materials for the detection of dengue virus infection
WO2014016362A1 (en) * 2012-07-24 2014-01-30 Sanofi Pasteur Vaccine compositions for prevention against dengue virus infection
TWI852899B (zh) 2014-09-02 2024-08-21 法商賽諾菲巴斯德公司 疫苗組合物
EP3031923A1 (en) * 2014-12-11 2016-06-15 Institut Pasteur Lentiviral vector-based japanese encephalitis immunogenic composition
CN104630160B (zh) * 2015-01-23 2018-04-27 中国农业科学院哈尔滨兽医研究所 表达西尼罗热病毒PrM/E蛋白的重组新城疫LaSota疫苗株
US10857222B2 (en) 2015-07-03 2020-12-08 Sanofi Pasteur Concomitant dengue and yellow fever vaccination
TW201718638A (zh) * 2015-07-21 2017-06-01 現代治療公司 傳染病疫苗
WO2017218339A1 (en) * 2016-06-13 2017-12-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nucleic acids encoding zika virus-like particles and their use in zika virus vaccines and diagnostic assays
US20180028643A1 (en) * 2016-06-21 2018-02-01 Brock Adam Kingstad-Bakke Zika virus vaccines using virus-like particles
US10898566B2 (en) 2016-09-19 2021-01-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Zika virus vaccines
BE1025121B1 (fr) * 2016-11-17 2018-11-05 Glaxosmithkline Biologicals Sa Constructions antigeniques du virus zika
WO2018152526A1 (en) 2017-02-20 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Zika virus vaccines
SG11202002933TA (en) 2017-10-05 2020-04-29 Sanofi Pasteur Compositions for booster vaccination against dengu
EP3530668A1 (en) * 2018-02-22 2019-08-28 Euroimmun Medizinische Labordiagnostika AG A novel assay for the diagnosis of viral infections
EP3755709A1 (en) * 2018-02-22 2020-12-30 Euroimmun Medizinische Labordiagnostika AG Assay for the diagnosis of viral infections
CN113583117B (zh) * 2018-04-04 2022-04-15 中国科学院微生物研究所 一种高灵敏度的黄热病毒人源单克隆抗体及其应用
CN108904793B (zh) * 2018-07-29 2021-03-30 首都医科大学附属北京友谊医院 预防流行性乙型脑炎的dna疫苗及其构建方法
US20220054620A1 (en) * 2018-12-20 2022-02-24 The Wistar Institute Of Anatomy And Biology Vaccines against powassan virus, and methods of using same
US20250276051A1 (en) * 2019-12-18 2025-09-04 Geneone Life Science, Inc. Powassan viral antigens and related compositions, and uses thereof to vaccinate and treat patients
KR102216078B1 (ko) * 2020-04-22 2021-02-16 국방과학연구소 유전자 백신으로 사용하기 위한 항원 유전자 전달용 발현 벡터 및 이를 포함하는 유전자 백신
US20230272405A1 (en) * 2020-06-22 2023-08-31 University Of Connecticut Flavivirus signal peptides, vaccine constructs, and methods therefor
WO2024097725A1 (en) * 2022-11-02 2024-05-10 Takeda Vaccines, Inc. A method for determining the infectivity of a virus

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998037911A1 (en) * 1997-02-28 1998-09-03 Oravax, Inc. Chimeric flavivirus vaccines
WO1999063095A1 (en) * 1998-06-04 1999-12-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nucleic acid vaccines for prevention of flavivirus infection

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1601438A (enExample) 1968-10-17 1970-08-24
JPS53133627A (en) 1977-04-25 1978-11-21 Nippon Seibutsu Kagaku Kenkiyu High purity deactivated vaccine for japanese encephalitis
JPH0768267B2 (ja) * 1986-06-05 1995-07-26 財団法人阪大微生物病研究会 フラビウイルス抗原
JPS634895A (ja) 1986-06-24 1988-01-09 Mitsubishi Electric Corp オゾン精製水供給装置
JPS63105682A (ja) 1986-10-23 1988-05-10 Mitsubishi Kasei Corp デングウイルス３型由来のｃＤＮＡ
FR2614219B1 (fr) 1987-04-23 1993-07-09 Materiels Annexes Dialyse Procede de fabrication de granules destines a la preparation de solutions de dialyse et installation pour sa mise en oeuvre.
JPH084508B2 (ja) * 1987-09-16 1996-01-24 国立予防衛生研究所長 組み換えワクチニアウイルス
US4783502A (en) 1987-12-03 1988-11-08 Ppg Industries, Inc. Stable nonaqueous polyurethane microparticle dispersion
JP2511494B2 (ja) * 1988-05-12 1996-06-26 善治 松浦 日本脳炎ウイルス表面抗原蛋白質の製造法
IL91304A0 (en) 1988-08-20 1990-03-19 Us Health Recombinant vaccinia virus for prevention of disease caused by flavivirus
JPH0425408A (ja) 1990-05-21 1992-01-29 Hitachi Ltd ペレタイジングシステムの自動連続運転制御方法
FR2665710A1 (fr) 1990-08-10 1992-02-14 Pasteur Institut Baculovirus recombinant exprimant les proteines e et ns1 de virus appartenant aux flaviviridae ou de virus apparentes aux flaviviridae, applications diagnostiques et therapeutiques.
MY109299A (en) 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
US5514375A (en) * 1990-08-15 1996-05-07 Virogenetics Corporation Flavivirus recombinant poxvirus vaccine
US5494671A (en) * 1990-08-27 1996-02-27 The United States Of America As Represented By The Department Of Health And Human Services C-terminally truncated dengue and Japanese encephalitis virus envelope proteins
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
CA2089661C (en) 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ATE197607T1 (de) 1991-09-19 2000-12-15 Us Health Chimäre und/oder wachstumgehemmte flaviviren
JPH05276941A (ja) 1992-02-28 1993-10-26 Nippon Zeon Co Ltd フラビウイルス科に属するウイルスの表面抗原タンパク質を含む非感染性の構造物粒子の製造方法
JPH07265093A (ja) 1994-03-30 1995-10-17 Chemo Sero Therapeut Res Inst 哺乳動物細胞を用いる日本脳炎ウイルス表面抗原蛋白質の製法
WO1996037221A1 (en) 1995-05-24 1996-11-28 Hawaii Biotechnology Group, Inc. Subunit vaccine against flavivirus infection
US6136561A (en) * 1995-05-24 2000-10-24 Hawaii Biotechnology Group, Inc. Methods of preparing carboxy-terminally truncated recombinant flavivirus envelope glycoproteins employing drosophila melanogaster expression systems
US6074865A (en) * 1995-07-20 2000-06-13 The United States Of America As Represented By The Secretary Of The Army Recombinant dengue virus DNA fragment
US6455509B1 (en) * 1996-06-04 2002-09-24 The United States Of America As Represented By The Secretary Of The Navy Dengue nucleic acid vaccines that induce neutralizing antibodies
US6962708B1 (en) * 1997-02-28 2005-11-08 Acambis, Inc. Chimeric flavivirus vaccines
DE69834041T2 (de) 1997-07-31 2006-12-14 Hawaii Biotech, Inc., Aiea Rekombinante dimerische hüllproteine als impfstoff gegen eine flavivirale infektion
DE69833388D1 (de) 1997-11-20 2006-04-13 Us Army Medical Res Materiel C Dna impfstoffe gegen zecken-flavivieren
US7227011B2 (en) * 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
WO2002083903A2 (en) 2001-02-28 2002-10-24 Brown University Research Foundation West nile virus epitopes and uses thereof
EP1372711A4 (en) 2001-03-12 2005-06-01 Univ Yale COMPOSITIONS AND METHODS OF WEST NIL VIRUS POLYPEPTIDES

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998037911A1 (en) * 1997-02-28 1998-09-03 Oravax, Inc. Chimeric flavivirus vaccines
WO1999063095A1 (en) * 1998-06-04 1999-12-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nucleic acid vaccines for prevention of flavivirus infection

Also Published As

Publication number Publication date
EP1935991B1 (en) 2012-11-07
CN1304575C (zh) 2007-03-14
US20030022849A1 (en) 2003-01-30
CN1500152A (zh) 2004-05-26
BRPI0208301B8 (pt) 2021-05-25
EP2332572B1 (en) 2014-01-08
EP2332572A1 (en) 2011-06-15
US8232379B2 (en) 2012-07-31
JP4448281B2 (ja) 2010-04-07
MXPA03008838A (es) 2004-10-15
US7632510B2 (en) 2009-12-15
JP2004532023A (ja) 2004-10-21
US20070166701A1 (en) 2007-07-19
US8221768B2 (en) 2012-07-17
CA2443323C (en) 2013-01-15
US20070166329A1 (en) 2007-07-19
WO2002081754A1 (en) 2002-10-17
US20100040643A1 (en) 2010-02-18
EP1935991A2 (en) 2008-06-25
BRPI0208301A8 (pt) 2018-11-27
HK1062836A1 (en) 2004-11-26
US20050163804A1 (en) 2005-07-28
KR20030092051A (ko) 2003-12-03
ZA200307580B (en) 2005-03-30
CN101002936A (zh) 2007-07-25
US7662394B2 (en) 2010-02-16
JP5236597B2 (ja) 2013-07-17
EP1383931A4 (en) 2004-12-22
NZ529106A (en) 2005-03-24
BR0208301A (pt) 2004-03-09
US7227011B2 (en) 2007-06-05
CA2443323A1 (en) 2002-10-17
EP1383931A1 (en) 2004-01-28
US20100003273A1 (en) 2010-01-07
US7521177B2 (en) 2009-04-21
BRPI0208301B1 (pt) 2019-12-24
JP2010017185A (ja) 2010-01-28
EP1935991A3 (en) 2008-09-10

Similar Documents

Publication Publication Date Title
KR100913984B1 (ko) 플라비바이러스 감염 예방용 핵산 백신
US8105609B2 (en) Flavivirus immunogens comprising extracellular viral particles composed of the premembrane (prM) and envelope (E) antigens
Egger et al. Reversible dissociation of the poliovirus replication complex: functions and interactions of its components in viral RNA synthesis
Jacobs et al. Dengue virus nonstructural protein 1 is expressed in a glycosyl‐phosphatidylinositol‐linked form that is capable of signal transduction
CN113631033B (zh) 与enpp1或enpp3缺乏有关的疾病的治疗
EP1721985A1 (en) Nucleic acid construct containing full-length genome of human hepatitis c virus, recombinant full-length virus genome replicative cell having the nucleic acid construct transferred thereinto and method of constructing hepatitis c viral particles
CN114616000A (zh) 载体组合物及其用于治疗溶酶体贮积症的方法
CN113444830A (zh) 用于检测SARS-CoV-2冠状病毒的试剂盒及其专用引物和探针
US20240148907A1 (en) Liver specific production of enpp1 or enpp3
RU2853644C2 (ru) Лечение заболеваний, включающих дефицит enpp1 или enpp3
US6673895B2 (en) Pro-apoptotic fragments of the dengue virus envelope glycoproteins
HK1062836B (en) Nucleic acid vaccines for prevention of flavivirus infection
US7341728B2 (en) Internalisation of virus into cells
HK40063782A (en) Treatment of diseases involving deficiency of enpp1 or enpp3
HK40063782B (zh) 与enpp1或enpp3缺乏有关的疾病的治疗
US20040101862A1 (en) Pro-apoptoic fragments of the dengue virus envelope glycoproteins

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20031002

Patent event code: PA01051R01D

Comment text: International Patent Application

AMND Amendment
PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20070329

Comment text: Request for Examination of Application

AMND Amendment
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20080228

Patent event code: PE09021S01D

AMND Amendment
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20080828

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20090226

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20080828

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

Patent event date: 20080228

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20090327

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20090226

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20090525

Appeal identifier: 2009101002858

Request date: 20090327

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20090327

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20090327

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20081028

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20080428

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20071203

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20031121

Patent event code: PB09011R02I

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

Patent event date: 20090525

Comment text: Decision to Grant Registration

Patent event code: PB07012S01D

Patent event date: 20090428

Comment text: Transfer of Trial File for Re-examination before a Trial

Patent event code: PB07011S01I

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20090819

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20090820

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20120802

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20120802

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20130801

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20130801

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20140806

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20140806

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20150805

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20150805

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20160808

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20160808

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20170809

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20170809

Start annual number: 9

End annual number: 9

FPAY Annual fee payment

Payment date: 20180808

Year of fee payment: 10

PR1001 Payment of annual fee

Payment date: 20180808

Start annual number: 10

End annual number: 10

FPAY Annual fee payment

Payment date: 20190807

Year of fee payment: 11

PR1001 Payment of annual fee

Payment date: 20190807

Start annual number: 11

End annual number: 11

PR1001 Payment of annual fee

Payment date: 20200812

Start annual number: 12

End annual number: 12

PR1001 Payment of annual fee

Payment date: 20210810

Start annual number: 13

End annual number: 13

PC1801 Expiration of term

Termination date: 20221004

Termination category: Expiration of duration